Meanwhile, DDR2 could be an effective target for enhancing tumor responses to anti-PD-1 according to recent research, which has proven that targeting DDR2 alongside PD-1 inhibitors exerts a more significant treatment effect among various cancers [134]. This evidence concerns the gene PDCD1 and cancer.